The stock is being held down by a CEO who keeps shooting himself in the foot, keeps moving goal posts, misses self-imposed milestones, finances operations through a vulture investor, is a terrible communicator and has no credibility with biotech institutional investors.
Good science (though it still unproven to regulators) does not make up for weak management and a board of directors that protects management at the expense of shareholders.
Agree. With the information we know today on all drug trial results this company should have a $5 to $10 billion market cap. Diagnosis! Market corruption. imo
It’s got nothing to do with BPs trying to prevent competition. It’s simply market makers/hedge funds addicted to dealing from the short side and making trading profits. The Fraudstein trading cabal latched onto it and they don’t want to let go. Unless and until they are forced to do so. Pretty simple, really. Their agents are familiar to everyone here.